Skip to main content

Molecular Partners Announces Participation in Scientific Conferences

Written by Customer Service on . Posted in Public Companies.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) —  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its team will participate in the European Hematology Association (EHA) Conference as well as other conferences in June. In addition, Novartis, the global license owner of ensovibep, will present preclinical data from the anti-SARS-CoV-2 program.

Conferences Details:

  • Poster; European Hematology Association (EHA) Conference
    • Title: MP0533, a New Multispecific DARPin CD3 Engager Targeting Three Tumor Associated Antigens, Induces Specific T-cell Activation and AML Tumor Killing in vivo
    • June 9-12, Vienna
  • Poster (Novartis); American Society for Microbiology (ASM Microbe)
    • Title: SARS-CoV-2 Omicron and Multi-variant Neutralization Activity of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid-19
    • June 9-13, Washington, DC
  • Poster; Dissecting Evolution and Heterogeneity of Single Cancer Cells
    • Title: Characterization of Tumor Infiltrating Dendritic Cells at the Single Cell Level
    • June 12-17, Easton, MA

Additional recent presentations:

  • Talks; Antibody Engineering & Therapeutics Europe
    • Title: Ensovibep, a SARS-CoV-2 Multi-Variant Neutralizing DARPin Therapeutic
    • Title: A Triple-targeting DARPin T-cell Engager Approach to Improve Safety and Efficacy for the Treatment of AML
    • June 7-9, 2022, Amsterdam

Presentations will be made available as available, through the Molecular Partners website
        
About Molecular Partners AG 
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter – @MolecularPrtnrs

CONTACT: For further details, please contact:
Seth Lewis
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Shai Biran, Ph.D.
shai.biran@molecularpartners.com
Tel: +1 978 254 6286

Thomas Schneckenburger, European IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 79 407 9952

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.